Clinical Trials: Adenocarcinoma

Arizona

Scottsdale; Scottsdale Medical Specialists
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Arkansas

Jonesboro; Northeast Arkansas Clinic
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

California

Bakersfield; Comp Blood & Cancer Center
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Beverly Hills; Tower Hematology Oncology Medi
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Campbell; Southbay Onc/Hem Partners
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Concord; Bay Area Cancer Research Group
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Duarte; City of Hope
SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Fountain Valley; Compassion Cancer Care Medical Group
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Fountain Valley; Pacific Coast Hematology/Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Modesto; Sutter Gould Medical Foundation
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Florida

Coral Springs; Northwest Hematology/Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Gainsville; Robert R. Carroll MD PA - Pr
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Tampa; Bay Area Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Georgia

Marietta; Northwest Georgia Onc Ctrs PC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Savannah; Memorial Health University Medical Center
CALGB 90401: A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Hormone Refractory Prostate Cancer

Illinois

Elgin; Sherman Health Systems
SWOG S0515 Phase II Advanced stage diffuse large B-cell NHL chemotherapy

Naperville; Hem Onc Consultants Ltd
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Quincy; Quincy Medical Group
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Indiana

Indianapolis; Hematology Oncology of Indiana
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Kansas

Wichita; Cancer Center of Kansas
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Kentucky

Louisville; Kentuckiana Cancer Institute
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Louisiana

Lafayette; Acadiana Medical Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Maryland

Bethesda; Oncology Care Associates
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Massachusetts

Pittsfield; Berkshire Hematology Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Michigan

Free Soil; West MI Reg Cancer & Blood Ctr
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Grand Rapids; Cancer & Hem Center of West MI
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Saint Joseph; Oncology Care Associates PLLC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Nebraska

Lincoln; Southeast Nebraska Cancer Centre
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Omaha; Hematology/Oncology Consultants PC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

New Jersey

Mountain Lakes; Onc & Hematology Specialists
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

New Mexico

Farmington; San Juan Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

New York

Jamaica; Biomedical Research Alliance of New York
Adenocarcinoma of the Pancreas- Metastatic (Stage IV)

Poughkeepsie; Vassar Brothers Medical Center
Trialing Assigning Individualized Options for Treatment - The TAILORx Trial

Rochester; Interlake Foundation Inc.Upstate NY Cancer Research & Education Foundation
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

North Carolina

Hickory; NW Carolina Onc & Hem - ICSL
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Ohio

Canton; Nashat Y. Gabrail Inc.
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Cincinnati; Oncology Hematology Care
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Columbus; Hematology Onc Consultants
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Oklahoma

Oklahoma City; Oncology Hematology Care
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Pennsylvania

Drexel Hill; Consultants in Medical Onc/Hem
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Pittsburgh; University of Pittsburgh Cancer Institute
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Tennessee

Bristol; Blue Ridge Medical Specialists
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Chattanooga; Chattanooga Oncology and Hematology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Germantown; The Jones Clinic
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Johnson City; McLeod Cancer & Blood Center
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Utah

Ogden; Northern Utah Associates
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Vermont

Rutland; Community Cancer Center
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer

Washington

Walla Walla; St. Mary Medical Center
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer